Immunic to Present New Clinical, Biomarker and Preclinical Data on Vidofludimus Calcium at MSToronto2026 - the 10th Joint ACTRIMS-ECTRIMS Meeting

ConferenceVidofludimus CalciumPositive

AI Analysis

Summary

Immunic will present four accepted abstracts on Vidofludimus Calcium at the MSToronto2026 conference, presenting clinical, biomarker and preclinical data on the investigational drug's profile in multiple sclerosis, including disability outcomes, immune activity, cognition and neuronal survival mechanisms.

Clinical Trial Data

Phase

Phase 2

Outcome Details

Presentation of new clinical, biomarker and preclinical data at MSToronto2026 conference

Importance:5/10

Sentiment:

0.30

multiple sclerosisvidofludimus calciumPhase 2clinical databiomarkerconference presentationdisability outcomescognition

Related Companies

$CGTX

Read the original article

Published by PR Newswire Biotech on October 7, 2026 12:00 PM

Read Original